We observed that BUD was not able to restore epithelial barrier dysfunction upon pharmacological inhibition of GSK-3β, indicating that GSK-3β activation is indispensable for the responsiveness of the epithelial barrier to BUD, in line with previous findings in lymphoma cells [32]. This evidence concerns the gene GSK3B and lymphoma.